Mathematical Modelling of Venom Immunotherapy

b Allergic hypersensitivity of type I for hymenoptera venoms is the most frequent reason for acute IgE- mediated anaphylactic reactions. The subcutaneous injection of increasing doses of purified allergen followed by long-term administration of an adequate maintenance dose over a period of 3- 5 years called venom immunotherapy (VIT) has been proven to be a very effective treatment achieving protection in about 96% of allergic patients. Even though the principle of hyposensitisation has been introduced already 90 years ago, the underlying immunoregulatory mechanisms of VIT remain poorly understood. Recent studies suggest a shift in cytokine production from a Th2 to a Th1 cytokine profile during therapy. In this paper, a mathematical model for T-cell regulation and a model for mast cell/basophil desensitisation are presented and analysed to explain the mechanism of conventional rush and ultra-rush VIT.

[1]  C. DeLisi,et al.  Receptor cross-linking and histamine release in basophils. , 1980, The Journal of biological chemistry.

[2]  M. Bachmann,et al.  The antigen dose determines T helper subset development by regulation of CD40 ligand , 2000, European journal of immunology.

[3]  M. Dembo,et al.  Theory of equilibrium binding of asymmetric bivalent haptens to cell surface antibody: application to histamine release from basophils. , 1978, Journal of immunology.

[4]  W. Paul,et al.  Mast cell lines produce lymphokines in response to cross-linkage of Fc epsilon RI or to calcium ionophores. , 1989, Nature.

[5]  V. Lukash,et al.  The Model of , 1972 .

[6]  E. Maggi,et al.  Genetic and Environmental Factors Contributing to the Onset of Allergic Disorders , 2000, International Archives of Allergy and Immunology.

[7]  J. Shelhamer,et al.  Effects of inhibitors of arachidonic acid metabolism on serotonin release from rat basophilic leukemia cells. , 1993, Immunopharmacology.

[8]  A. Abbas,et al.  Cellular and Molecular Immunology , 1991 .

[9]  R. Coffman,et al.  Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. , 1986, Journal of immunology.

[10]  R. Ghirlando,et al.  Thermodynamics of the interaction of human immunoglobulin E with its high-affinity receptor Fc epsilon RI. , 1998, Biochemistry.

[11]  A. Weinberg,et al.  IL-4 directs the development of Th2-like helper effectors. , 1990, Journal of immunology.

[12]  U. Behn,et al.  MODELING TH1-TH2 REGULATION, ALLERGY, AND HYPOSENSITIZATION , 2000 .

[13]  J. Murray,et al.  How the MHC selects Th1/Th2 immunity. , 1998, Immunology today.

[14]  C. Heusser,et al.  Antigen Dose-Dependent Regulation of Bε-Memory Cell Expression , 1991 .

[15]  D. Charpin,et al.  Rapid Hymenoptera venom immunotherapy: comparative safety of three protocols , 1993, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[16]  A. Sette,et al.  Peptide analogs with different affinites for MHC alter the cytokine profile of T helper cells. , 1996, International immunology.

[17]  C. Parish.  The Relationship Between Humoral and Cell‐Mediated Immunity , 1972, Transplantation reviews.

[18]  H. Fischer,et al.  ULTRARUSH-HYPOSENSIBILISIERUNG MIT HYMENOPTERENGIFTEN , 1996 .

[19]  A. Sher,et al.  Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon gamma production and diminishes interleukin 4 inhibition of such priming. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[20]  G. Kroemer,et al.  Compartmentalization of the peripheral immune system. , 1993, Advances in immunology.

[21]  R. V. van Neerven,et al.  The CC-chemokine receptor 5 (CCR5) is a marker of, but not essential for the development of human Th1 cells. , 1999, Tissue antigens.

[22]  Kenneth M. Murphy,et al.  Functional diversity of helper T lymphocytes , 1996, Nature.

[23]  Suneet Agarwal,et al.  Modulation of chromatin structure regulates cytokine gene expression during T cell differentiation. , 1998, Immunity.

[24]  D. Charpin,et al.  Protocole de désensibilisation accéléré aux venins d'hyménoptères , 1988 .

[25]  S. Romagnani.  Th1 and Th2 cells in health and disease. , 1996 .

[26]  P. Kalinski,et al.  The role of antigen-presenting cells in the regulation of allergen-specific T cell responses. , 1998, Current opinion in immunology.

[27]  R. V. van Lier,et al.  CD30 expression does not discriminate between human Th1- and Th2-type T cells. , 1996, Journal of immunology.

[28]  T. Luger,et al.  Safety of a two-day ultrarush insect venom immunotherapy protocol in comparison with protocols of longer duration and involving a larger number of injections. , 2000, The Journal of allergy and clinical immunology.

[29]  D. Umetsu,et al.  Interleukin 4 production by CD4+ T cells from allergic individuals is modulated by antigen concentration and antigen-presenting cell type , 1995, The Journal of experimental medicine.

[30]  L. Segel,et al.  Th1 or Th2: How an appropriate T helper response can be made , 2001, Bulletin of mathematical biology.

[31]  K. Murphy,et al.  The effect of antigen dose on CD4+ T helper cell phenotype development in a T cell receptor-alpha beta-transgenic model , 1995, The Journal of experimental medicine.

[32]  R. Siraganian,et al.  IgE‐induced histamine release from rat basophilic leukemia cell lines: isolation of releasing and nonreleasing clones , 1981, European journal of immunology.

[33]  A. O’Garra,et al.  Cutting Edge: Chromatin Remodeling at the IL-4/IL-13 Intergenic Regulatory Region for Th2-Specific Cytokine Gene Cluster1 , 2000, The Journal of Immunology.

[34]  R. Rodríguez-Roisín,et al.  Evaluation of CD30 as a marker for th2 lymphocytes in bronchoalveolar lavage in interstitial lung diseases. , 2000, Respiratory medicine.

[35]  J. Moore,et al.  The mechanism of the calcium signal and correlation with histamine release in 2H3 cells. , 1984, The Journal of biological chemistry.

[36]  S. Romagnani.  Regulatory role of IL4 and other cytokines in the function and development of human T-cell clones. , 1993, Research in immunology.

[37]  A. Schuerwegh,et al.  Wasp venom immunotherapy induces a shift from IL‐4‐producing towards interferon‐gamma‐producing CD4+ and CD8+ T lymphocytes , 2001, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[38]  C. Akdis,et al.  Determinants and Mechanisms of Human Immune Responses to Bee Venom Phospholipase A2 , 1998, International Archives of Allergy and Immunology.

[39]  J. Deighton,et al.  Bee venom immunotherapy induces a shift in cytokine responses from a TH‐2 to a TH‐1 dominant pattern: comparison of rush and conventional immunotherapy , 1995, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[40]  S. Szabo,et al.  T helper differentiation proceeds through Stat1-dependent, Stat4-dependent and Stat4-independent phases. , 1999, Current topics in microbiology and immunology.

[41]  Santa Jeremy Ono,et al.  Molecular genetics of allergic diseases. , 2000, Annual review of immunology.

[42]  F. Sallusto,et al.  Dynamics of T lymphocyte responses: intermediates, effectors, and memory cells. , 2000, Science.

[43]  D. Golden,et al.  Survey of patients after discontinuing venom immunotherapy. , 2000, The Journal of allergy and clinical immunology.

[44]  A. Sette,et al.  Major histocompatibility complex binding affinity of an antigenic determinant is crucial for the differential secretion of interleukin 4/5 or interferon gamma by T cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[45]  Alan S. Perelson,et al.  Quantifying Aggregation of IgE-FcϵRI by Multivalent Antigen , 1999 .

[46]  P. Allen,et al.  TCR-independent pathways mediate the effects of antigen dose and altered peptide ligands on Th cell polarization. , 1999, Journal of immunology.

[47]  H. Bielefeldt-Ohmann,et al.  Establishment of stable, cell-mediated immunity that makes "susceptible" mice resistant to Leishmania major. , 1992, Science.

[48]  K. Else,et al.  Low‐level infection with Trichuris muris significantly affects the polarization of the CD4 response , 1994, European journal of immunology.

[49]  L. Noon.  Prophylactic inoculation against hay fever. , 1911, International archives of allergy and applied immunology.

[50]  M. Dembo,et al.  A model of cell activation and desensitization by surface immunoglobin: The case of histamine release from human basophils , 1980, Cell.

[51]  S. Romagnani,et al.  The Th1/Th2 paradigm. , 1997, Immunology today.

[52]  B. Helm,et al.  Potential allergens stimulate the release of mediators of the allergic response from cells of mast cell lineage in the absence of sensitization with antigen‐specific IgE , 1996, European journal of immunology.

[53]  R. Reisman,et al.  Venom immunotherapy: 10 years of experience with administration of single venoms and 50 μg maintenance doses , 1992 .

[54]  L. Lichtenstein,et al.  A controlled trial of immunotherapy in insect hypersensitivity. , 1978, The New England journal of medicine.

[55]  L. Segel,et al.  Modeling immunotherapy for allergy. , 1996, Bulletin of mathematical biology.

[56]  R. Confino‐Cohen,et al.  Maintenance venom immunotherapy administered at 3-month intervals is both safe and efficacious. , 2001, The Journal of allergy and clinical immunology.

[57]  M. Mancino,et al.  Immunologic evaluation of 24 month course of sublingual immunotherapy. , 1994, Allergologia et immunopathologia.

[58]  R. Flavell,et al.  T-cell subsets: transcriptional control in the Th1/Th2 decision. , 1997, Current biology : CB.

[59]  S. Romagnani.  Human TH1 and TH2 subsets: doubt no more. , 1991, Immunology today.